Toxoplasmic encephalitis relapse rates with pyrimethamine-based therapy: systematic review and meta-analysis

References

• Holland GN. Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Am J Ophthalmol. 2003;136(6):973–88.10.1016/j.ajo.2003.09.040
   PubMed Web of Science ®Google Scholar
• Dalimi A, Abdoli A. Latent toxoplasmosis and human. Iran J Parasitol. 2012;7(1):1–17.
   Web of Science ®Google Scholar
• Parasites – Toxoplasmosis (Toxoplasma infection) : Resources for Health Professionals: Centers for Disease Control and Prevention; [Page last updated 2015 December 14].
   Google Scholar
• Shin DW, Cha DY, Hua QJ, et al. Seroprevalence of Toxoplasma gondii Infection and characteristics of seropositive patients in general hospitals in Daejeon, Korea. Korean J Parasitol. 2009;47(2):125–30.10.3347/kjp.2009.47.2.125
   PubMed Web of Science ®Google Scholar
• Xiao Y, Yin J, Jiang N, et al. Seroepidemiology of human Toxoplasma gondii infection in China. BMC Infect Dis. 2010;10:4.10.1186/1471-2334-10-4
   PubMed Web of Science ®Google Scholar
• Kamani J, Mani AU, Egwu GO, et al. Seroprevalence of human infection with Toxoplasma gondii and the associated risk factors, in Maiduguri, Borno state, Nigeria. Ann Trop Med Parasitol. 2009;103(4):317–21.10.1179/136485909X435094
   PubMed Web of Science ®Google Scholar
• Swai ES, Schoonman L. Seroprevalence of Toxoplasma gondii infection amongst residents of Tanga district in North-East Tanzania. Tanzan J Health Res. 2009;11(4):205–9.
   PubMedGoogle Scholar
• Fromont EG, Riche B, Rabilloud M. Toxoplasma seroprevalence in a rural population in France: detection of a household effect. BMC Infect Dis. 2009;9:1217.10.1186/1471-2334-9-76
   Web of Science ®Google Scholar
• Dubey JP, Lago EG, Gennari SM, et al. Toxoplasmosis in humans and animals in Brazil: high prevalence, high burden of disease, and epidemiology. Parasitology. 2012;139(11):1375–424.10.1017/S0031182012000765
   PubMed Web of Science ®Google Scholar
• Derouin F, Pelloux H. Parasitology ESGoC. Prevention of toxoplasmosis in transplant patients. Clin Microbiol Infect. 2008;14(12):1089–101.10.1111/j.1469-0691.2008.02091.x
   PubMed Web of Science ®Google Scholar
• Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004;363(9425):1965–76.10.1016/S0140-6736(04)16412-X
   PubMed Web of Science ®Google Scholar
• Pereira-Chioccola VL, Vidal JE, Su C. Toxoplasma gondii infection and cerebral toxoplasmosis in HIV-infected patients. Future Microbiol. 2009;4(10):1363–79.10.2217/fmb.09.89
   PubMed Web of Science ®Google Scholar
• Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis. 1992;15(2):211–22.10.1093/clinids/15.2.211
   PubMed Web of Science ®Google Scholar
• Grant IH, Gold JW, Rosenblum M, et al. Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS. AIDS. 1990;4(6):519–22.10.1097/00002030-199006000-00004
   PubMed Web of Science ®Google Scholar
• Ruskin J, Remington JS. Toxoplasmosis in the compromised host. Ann Intern Med. 1976;84(2):193–9.10.7326/0003-4819-84-2-193
   PubMed Web of Science ®Google Scholar
• Vora NM, Holman RC, Mehal JM, et al. Burden of encephalitis-associated hospitalizations in the United States, 1998–2010. Neurology. 2014;82(5):443–51.10.1212/WNL.0000000000000086
   PubMed Web of Science ®Google Scholar
• Panel on antiretroviral guidelines for adults and adolescents; guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Washington, DC: Department of Health and Human Services; [updated 2015 October 19]. Available from: https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/322/toxo.
   Google Scholar
• Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. Pharmacotherapy. 2004;24(7):856–70.10.1592/phco.24.9.856.36106
   PubMed Web of Science ®Google Scholar
• Waxman S, Metz J, Herbert V. Defective DNA synthesis in human megaloblastic bone marrow: effects of homocysteine and methionine. J Clin Invest. 1969;48(2):284–9.10.1172/JCI105984
   PubMed Web of Science ®Google Scholar
• Martin-Blondel G, Alvarez M, Delobel P, et al. Toxoplasmic encephalitis IRIS in HIV-infected patients: a case series and review of the literature. J Neurol Neurosurg Psychiatry. 2011;82(6):691–3.10.1136/jnnp.2009.199919
   PubMed Web of Science ®Google Scholar
• Wei HX, Wei SS, Lindsay DS, et al. A systematic review and meta-analysis of the efficacy of anti-Toxoplasma gondii medicines in humans. PLoS One. 2015;10(9):e0138204.10.1371/journal.pone.0138204
   PubMed Web of Science ®Google Scholar
• Yan J, Huang B, Liu G, et al. Meta-analysis of prevention and treatment of toxoplasmic encephalitis in HIV-infected patients. Acta Trop. 2013;127(3):236–44.10.1016/j.actatropica.2013.05.006
   PubMed Web of Science ®Google Scholar
• Hernandez AV, Thota P, Pellegrino D, et al. A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: is trimethoprim-sulfamethoxazole a real option? HIV Med. doi:10.1111/hiv.12402.
   Google Scholar
• Rajapakse S, Chrishan Shivanthan M, Samaranayake N, et al. Antibiotics for human toxoplasmosis: a systematic review of randomized trials. Pathog Glob Health. 2013;107(4):162–9.10.1179/2047773213Y.0000000094
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med. 1998;338(13):853–60.10.1056/NEJM199803263381301
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34.10.1016/j.jclinepi.2009.06.006
   PubMed Web of Science ®Google Scholar
• National heart lung and blood institute study quality assessment tools. Available from: https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools
   Google Scholar
• Freeman FM, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat. 1950;21(4):607–11.10.1214/aoms/1177729756
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.10.1016/0197-2456(86)90046-2
   PubMedGoogle Scholar
• Cochrane handbook for systematic reviews of interventions Available from: http://training.cochrane.org/handbook.
   Google Scholar
• Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54(10):1046–55.10.1016/S0895-4356(01)00377-8
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.10.1136/bmj.315.7109.629
   PubMed Web of Science ®Google Scholar
• Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.10.1136/bmj.d4002
   PubMed Web of Science ®Google Scholar
• Ruf B, Schürmann D, Bergmann F, et al. Efficacy of pyrimethamine/sulfadoxine in the prevention of toxoplasmic encephalitis relapses and pneumocystis carinii pneumonia in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 1993;12(5):325–9.10.1007/BF01964427
   PubMed Web of Science ®Google Scholar
• Renold C, Sugar A, Chave JP, et al. Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome. Medicine (Baltimore). 1992;71(4):224–39.10.1097/00005792-199207000-00005
   PubMed Web of Science ®Google Scholar
• Katlama C, Wit S, O’Doherty E, et al. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clinical Infect Dis. [Internet]. 1996; 22(2):268–75. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/960/CN-00130960/frame.html.
   PubMed Web of Science ®Google Scholar
• Foppa CU, Bini T, Gregis G, et al. A retrospective study of primary and maintenance therapy of toxoplasmic encephalitis with oral clindamycin and pyrimethamine. Eur J Clin Microbiol Infect Dis. 1991;10(3):187–9.10.1007/BF01964458
   PubMed Web of Science ®Google Scholar
• Leport C, Tournerie C, Raguin G, et al. Long-term follow-up of patients with AIDS on maintenance therapy for toxoplasmosis. Eur J Clin Microbiol Infect Dis. 1991;10(3):191–3.10.1007/BF01964460
   PubMed Web of Science ®Google Scholar
• Leport C, Vilde JL, Katlama C, et al. Cerebral toxoplasmosis in immunosuppressed patients: diagnosis and treatment. Ann Med Interne (Paris). 1987;138(1):30–3.
   PubMedGoogle Scholar
• Podzamczer D, Miro JM, Bolao F, et al. Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish toxoplasmosis study group. Ann Intern Med. 1995;123(3):175–80.10.7326/0003-4819-123-3-199508010-00003
   PubMed Web of Science ®Google Scholar
• Altes J, Salas A, Ricart C, et al. Cerebral toxoplasmosis in patients with AIDS. Arch Neurobiol (Madr). 1989;52(Suppl 1):121–6.
   PubMedGoogle Scholar
• de Gans J, Portegies P, Reiss P, et al. Pyrimethamine alone as maintenance therapy for central nervous system toxoplasmosis in 38 patients with AIDS. J Acquir Immune Defic Syndr. 1992;5(2):137–42.
   PubMed Web of Science ®Google Scholar
• Pedrol E, Gonzalez-Clemente JM, Gatell JM, et al. Central nervous system toxoplasmosis in AIDS patients: efficacy of an intermittent maintenance therapy. AIDS. 1990;4(6):511–8.10.1097/00002030-199006000-00003
   PubMed Web of Science ®Google Scholar
• Leport C, Raffi F, Matheron S, et al. Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy. Am J Med. 1988;84(1):94–100.10.1016/0002-9343(88)90014-9
   PubMed Web of Science ®Google Scholar
• Dannemann BR, Israelski DM, Remington JS. Treatment of toxoplasmic encephalitis with intravenous clindamycin. Arch Intern Med. 1988;148(11):2477–82.10.1001/archinte.1988.00380110109023
   PubMedGoogle Scholar
• Ruf B, Pohle H. Role of clindamycin in the treatment of acute toxoplasmosis of the central nervous system. Eur J Clin Microbiol Infect Dis. 1991;10(3):183–6.10.1007/BF01964457
   PubMed Web of Science ®Google Scholar
• Orefice G, Carrieri PB, Chirianni A, et al. Cerebral toxoplasmosis and AIDS. Clinical, neuroradiological and immunological findings in 15 patients. Acta Neurol. 1992;14(4–6):493–502.
   PubMedGoogle Scholar
• Torre D, Casari S, Speranza F, et al. Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Antimicrob Agents Chemother. 1998;42(6):1346–9.
   PubMed Web of Science ®Google Scholar
• Canessa A, Del Bono V, De Leo P, et al. Cotrimoxazole therapy of Toxoplasma gondii encephalitis in AIDS patients. Eur J Clin Microbiol Infect Dis. 1992;11(2):125–30.10.1007/BF01967063
   PubMed Web of Science ®Google Scholar
• Bouree P, Dumazedier D, Magdeleine C, et al. Cerebral toxoplasmosis and AIDS in martinique. Med Trop (Mars). 1997;57(3):259–61.
   PubMedGoogle Scholar
• Ragnaud JM, Morlat P, Dupon M, et al. Cerebral toxoplasmosis in AIDS. 73 cases. Clinical epidemiology group on AIDS in aquitania. Presse Med. 1993;22(19):903–8.
   PubMed Web of Science ®Google Scholar
• Arendt G, von Giesen HJ, Hefter H, et al. Long-term course and outcome in AIDS patients with cerebral toxoplasmosis. Acta Neurol Scand. 1999;100(3):178–84.
   PubMed Web of Science ®Google Scholar
• Chirgwin K, Hafner R, Leport C, et al. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039. Clinical Infect Dis. [Internet]. 2002; 34(9):1243–50. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/407/CN-00379407/frame.html.
   PubMed Web of Science ®Google Scholar
• Davarpanah M, Mehrabani D, Neirami R, et al. Toxoplasmosis in HIV/AIDS patients in Shiraz, southern Iran. Iran Red Crescent Med J. 2007;2007(1):22–7.
   Google Scholar
• Langmann P, Schirmer D, Zilly M, et al. Drug monitoring of pyrimethamine during maintenance therapy of toxoplasmic encephalitis in patients with advanced HIV infection during HAART. Med Sci Monit. 2004;10(5):PI65–9.
   Google Scholar
• Podzamczer D, Miro JM, Ferrer E, et al. Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish toxoplasmosis study group. Eur J Clin Microbiol Infect Dis. 2000;19(2):89–95.10.1007/s100960050436
   PubMed Web of Science ®Google Scholar
• Vidal JE, Hernandez AV, De Oliveira ACP, et al. Cerebral toxoplasmosis in HIV-positive patients in Brazil: clinical features and predictors of treatment response in the HAART era. AIDS Patient Care St. 2005;19(10):626–34.10.1089/apc.2005.19.626
   PubMed Web of Science ®Google Scholar
• Ragnaud J, Morlat P, Dupon M, et al. Relapse of brain toxoplasmosis in 25 AIDS patients. Med Mal Infect. 1993;23(11):791–5.10.1016/S0399-077X(05)81283-1
   Web of Science ®Google Scholar
• Walckenaer G, Leport C, Longuet P, et al. Recurrence of cerebral toxoplasmosis in 15 AIDS patients. Ann Med Interne (Paris). 1994;145(3):181–4.
   PubMedGoogle Scholar
• Ferrer S, Fuentes I, Domingo P, et al. Cerebral toxoplasmosis in patients with human immunodeficiency virus (HIV) infection. Clinico-radiological and therapeutic aspects in 63 patients. Anales de medicina interna (Madrid, Spain: 1984). 1996;13(1):4–8.
   Google Scholar
• Gonzalez-Clemente JM, Miro JM, Pedrol E, et al. Encephalic toxoplasmosis in patients with the acquired immunodeficiency syndrome. A clinico-radiological study and the therapeutic results in 78 cases. Med Clin (Barc). 1990;95(12):441–6.
   PubMed Web of Science ®Google Scholar
• Beraud G, Pierre-Francois S, Foltzer A, et al. Cotrimoxazole for treatment of cerebral toxoplasmosis: an observational cohort study during 1994–2006. Am J Trop Med Hyg. 2009;80(4):583–7.
   PubMed Web of Science ®Google Scholar
• Chaddha DS, Kalra SP, Singh AP, et al. Toxoplasmic encephalitis in acquired immunodeficiency syndrome. J Assoc Physicians India. 1999;47(7):680–4.
   PubMedGoogle Scholar
• Duval X, Pajot O, Le Moing V, et al. Maintenance therapy with cotrimoxazole for toxoplasmic encephalitis in the era of highly active antiretroviral therapy. Aids. 2004;18(9):1342–4.10.1097/00002030-200406180-00016
   PubMed Web of Science ®Google Scholar
• Smadja D, Fournerie P, Cabre P, et al. Efficacy and good tolerance of cotrimoxazole as treatment of cerebral toxoplasmosis in AIDS. Presse Med. 1998;27(26):1315–20.
   PubMed Web of Science ®Google Scholar
• Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet. 2005;365(9453):82–93.10.1016/S0140-6736(04)17670-8
   PubMed Web of Science ®Google Scholar
• Shrier I, Boivin JF, Steele RJ, et al. Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? a critical examination of underlying principles. Am J Epidemiol. 2007;166(10):1203–19.10.1093/aje/kwm189
   PubMed Web of Science ®Google Scholar
• Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2012;16(4):447–54.10.5588/ijtld.11.0451
   PubMed Web of Science ®Google Scholar